Regeneron Pharmaceuticals Inc (LTS:0R2M)
$ 676.38 +3.995 (+0.59%) Market Cap: 70.47 Bil Enterprise Value: 64.42 Bil PE Ratio: 16.38 PB Ratio: 2.25 GF Score: 87/100

Regeneron Pharmaceuticals Inc at Leerink Global Healthcare Conference Transcript

Mar 11, 2026 / 02:40PM GMT
Release Date Price: $775.68 (-0.17%)
David Risinger
Leerink Partners LLC - Analyst

So we'll kick it off here. Thanks for your patience. So I'm Dave Reisinger. It's very much my, pleasure to welcome members of the Regeneron Management team. So with us is Marion McCourt, who's executive Vice President of commercial, and Ryan Crowe, senior Vice President of Investor relations and, strategy.

So, thanks again for being here with us. I thought that. Maybe I'd turned it over to you to provide some just opening comments about the the prospects for the business this year.

Absolutely.

Ryan Crowe
Regeneron Pharmaceuticals Inc - Senior Vice President of Investor Relations & Strategy

Maybe I'll start and we really truly appreciate the opportunity to be here, Dave Learing conference is always something we we plan to attend every year and excited to be back, and today we think we have a thoughtful discussion around the commercial momentum we have in our business as well as the deep diverse and diversified pipeline. And how we're executing all across that as well as kind of our

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot